Literature DB >> 2326866

Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy.

R E Champlin1, W G Ho, S D Nimer, J G Gajewski, M Selch, M Burnison, G Holley, P Yam, L Petz, D J Winston.   

Abstract

Twenty-nine patients with severe aplastic anemia were entered into a study of pre- and posttransplant immunosuppressive therapy for bone marrow transplantation. Four of twenty-five previously transfused recipients prepared with cyclophosphamide 200 mg/kg and total-lymphoid irradiation 3 Gy experienced graft failure, indicating that this regimen was inadequate to ensure sustained engraftment. Posttransplant treatment with cyclosporine and methotrexate resulted in an actuarial incidence for grade greater than or equal to 2 graft-versus-host disease of 22 +/- 16%. Actuarial survival was 78 +/- 15%. These data indicate that more effective treatment is necessary to prevent graft failure, but since many patients can be successfully retransplanted, overall survival is comparable to other recent studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2326866

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens.

Authors:  Richard E Champlin; Waleska S Perez; Jakob R Passweg; John P Klein; Bruce M Camitta; Eliane Gluckman; Christopher N Bredeson; Mary Eapen; Mary M Horowitz
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

Review 2.  Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products.

Authors:  Reuven Or; Memet Aker; Michael Yechiel Shapira; Igor Resnick; Menachem Bitan; Simcha Samuel; Shimon Slavin
Journal:  Springer Semin Immunopathol       Date:  2004-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.